Search

Your search keyword '"Virus et Immunité"' showing total 263 results

Search Constraints

Start Over You searched for: Author "Virus et Immunité" Remove constraint Author: "Virus et Immunité"
263 results on '"Virus et Immunité"'

Search Results

1. Transient viral exposure drives functionally-coordinated humoral immune responses in HIV-1 post-treatment controllers

2. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells

3. Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis

4. Human Claudin-Derived Peptides Block the Membrane Fusion Process of Zika Virus and Are Broad Flavivirus Inhibitors

5. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

6. Species-Specific Molecular Barriers to SARS-CoV-2 Replication in Bat Cells

7. Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5 dynamics depending on its dimerization status

8. Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

9. Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2

10. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients

11. Towards SARS-CoV-2 serotypes?

12. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

13. Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine

14. Severe relapse of SARS‐CoV‐2 infection in a kidney transplant recipient with negative nasopharyngeal SARS‐CoV‐2 RT‐PCR after rituximab

15. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma

16. Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort

17. High negative predictive value of RT-PCR in patients with high likelihood of SARS-CoV-2 infection

18. Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study

19. C910 chemical compound inhibits the traffiking of several bacterial AB toxins with cross-protection against influenza virus

20. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

21. COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection

22. Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques

23. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection

24. Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study

25. Bystander CD4 T-cell death is inhibited by broadly neutralizing anti-HIV antibodies only at levels blocking cell-to-cell viral transmission

26. SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation

27. Characteristics Associated with Olfactory and Taste Disorders in COVID-19

28. A monocyte/dendritic cell molecular signature of SARS-CoV-2-related multisystem inflammatory syndrome in children with severe myocarditis

29. The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling

30. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection

31. Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual

32. SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance

33. Analysis of T‐cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in patients with chilblain‐like lesions during the COVID‐19 pandemic

34. Distinct systemic and mucosal immune responses to SARS-CoV-2

35. SARS-CoV-2 infection damages airway motile cilia and impairs mucociliary clearance

36. A monocyte/dendritic cell molecular signature of SARS-CoV2-related multisystem inflammatory syndrome in children (MIS-C) with severe myocarditis

37. SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020

38. Sera neutralizing activities against SARS-CoV-2 and multiple variants six month after hospitalization for COVID-19

39. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

40. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells

41. Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection

42. Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins

43. Cluster of COVID-19 in northern France: A retrospective closed cohort study

44. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

45. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

46. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS‐CoV‐2 Spike protein‐containing virus

47. Syncytia formation by SARS‐CoV‐2‐infected cells

48. IgA dominates the early neutralizing antibody response to SARS-CoV-2

49. Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders

50. Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

Catalog

Books, media, physical & digital resources